Liothyronine (T3) vs Retatrutide
FDA Approved vs Extensively Studied
monitor Mechanism-based · 50% Both Liothyronine (T3) and Retatrutide promote fat breakdown. While additive fat loss is possible, excessive lipolysis can cause rapid free fatty acid elevation and cardiac strain. Monitor heart rate and adjust doses gradually.
Molecular Data
Liothyronine (T3) Retatrutide
Weight 650.97 Da 4,731.33 Da
Half-life ~1 day ~6 days
Chain — 39 amino acids
Type Thyroid hormone (C15H12I3NO4) Triple GLP-1/GIP/glucagon agonist
Key Benefits
Liothyronine (T3)
01 Direct and rapid increase in basal metabolic rate
02 Enhanced fat oxidation and lipolysis
03 Improved energy levels and reduction of hypothyroid fatigue
04 Faster-acting than T4 with effects noticeable within hours to days
05 Useful when peripheral T4-to-T3 conversion is impaired (illness, caloric deficit, stress)
06 Supports body temperature regulation and thermogenesis
07 Can improve cognitive clarity and reduce brain fog associated with low thyroid function
Retatrutide
01 Superior weight loss (24.2% at 48 weeks)
02 Improved glycemic control (HbA1c reduction up to 2.16%)
03 Enhanced cardiovascular benefits
04 Hepatic fat reduction (up to 82%)
05 Triple mechanism addresses obesity through multiple pathways
Dosing Protocols
Liothyronine (T3)
25-75 mcg/day (replacement) / 1-2x daily (oral)
Retatrutide
0.5mg starting, titrate up to 8-12mg weekly / Once weekly (same day each week)
Starting Dose (Week 1-4) 0.5mg Once weekly
Low Maintenance (Week 4-8) 1mg Once weekly
Escalation (Week 8-12) 2mg Once weekly
Moderate (Week 12-16) 4mg Once weekly
Advanced (Week 16-20) 8mg Once weekly
Maximum Efficacy (Week 20+) 12mg Once weekly
Side Effects
Liothyronine (T3)
Tachycardia and palpitations (increased heart rate, especially at higher doses)
Anxiety, nervousness, and irritability
Insomnia and disrupted sleep architecture
Increased sweating and heat intolerance
Tremor (fine hand tremor, similar to hyperthyroid presentation)
Increased appetite despite accelerated metabolism
Loose stools or increased bowel frequency
Retatrutide
Gastrointestinal effects (nausea, vomiting, diarrhea)—typically mild to moderate
Heart rate increases—common especially in first 24 weeks
Appetite suppression
Mild dehydration
Contraindications
Untreated adrenal insufficiency (must correct cortisol deficiency before starting T3)
Acute myocardial infarction or unstable angina
Thyrotoxicosis or untreated hyperthyroidism
Known hypersensitivity to liothyronine or any tablet excipients
Uncorrected adrenal cortical insufficiency (risk of adrenal crisis)
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome
Severe renal impairment
Research Evidence
Liothyronine (T3) Retatrutide
Status FDA Approved Extensively Studied
References 5 studies 6 studies
Latest September 2023 2025-10
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.